Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05568719 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

StatusRecruiting
PhasePhase 3
SponsorPfizer
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 39 sites
  2. Site details revised at 1 of 39 sites
  3. Trial sites expanded: 23 → 39 locations
    • Secondary endpoints: details revised at 6 of 9 entries
    • Publications: details revised at 5 of 5 entries
  4. Study sites: 22 to 23v25
  5. Trial sites expanded: 19 → 22 locationsv24
  6. Trial sites expanded: 8 → 19 locationsv23
  7. Trial sites reduced: 17 → 8 locationsv22
  8. Re-verified, no change to tracked fieldsv21
  9. Study sites: 16 to 17v20
  10. Re-verified, no change to tracked fieldsv19
  11. Enrollment target: 263 to 173
    • Study sites: 12 to 16
    v18
  12. Site details revised at 4 of 12 sitesv17
  13. Study sites: 11 to 12v16
  14. Primary and study completion dates: Sep 3, 2039 to Feb 25, 2040v15
  15. Study sites: 6 to 11v14
  16. Primary and study completion dates: Apr 8, 2038 to Sep 3, 2039
    • Site details revised at 2 of 6 sites
    v13
  17. Site details revised at 1 of 6 sitesv12
  18. Primary and study completion dates: Jan 29, 2038 to Apr 8, 2038v11
  19. Study sites: 5 to 6
    • Primary and study completion dates: Jan 6, 2038 to Jan 29, 2038
    v10
  20. Study sites: 4 to 5
    • Primary and study completion dates: Nov 14, 2037 to Jan 6, 2038
    v9
  21. Study sites: 3 to 4v8
  22. Phase: Not specified to Phase 3
    • Enrollment target: 250 to 263
    • Study sites: 2 to 3
    • Study title shortened, about 2 words
    v7
  23. Study sites: 1 to 2v6
  24. 2 versions Re-verified since Mar 16, 2023, no change to tracked fieldsv4-v5
  25. Primary and study completion dates: Oct 19, 2037 to Nov 14, 2037
    • Start date changed from estimate of Jan 13, 2023 to Dec 28, 2022
    v3
  26. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Sep 7, 2034 to Oct 19, 2037
    • Start date: Oct 31, 2022 to Jan 13, 2023
    • Study sites: 0 to 1
    v2
  27. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
436 trials monitored
See 32 trials at risk
Hemophilia
241 trials monitored
See 12 trials at risk
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Trial Details
NCT Number NCT05568719
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Hemophilia A, Hemophilia B
Related terms Hemophilia A, Hemophilia B, Hemorrhage
Enrollment 173 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov